Attralus Receives U.S. FDA Orphan Drug Designation for AT-01 (Iodine (I-124) Evuzamitide), an Investigational Diagnostic for the Management of Transthyretin Amyloidosis
August 08, 2022 07:00 ET
|
Attralus, Inc
SAN FRANCISCO, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic...
Positive New Data from Phase 1/2 Trial of AT-01 (Iodine I-124 Evuzamitide) Presented at 2022 Society of Nuclear Medicine & Molecular Imaging Annual Meeting
June 14, 2022 11:45 ET
|
Attralus, Inc
AT-01 is the first pan-amyloid imaging agent capable of detecting diverse types of systemic amyloidosisAT-01 visualizes and quantifies organ-specific changes in amyloid load over time AT-01 detected...
Attralus to Present New AT-01 Data at 2022 Society of Nuclear Medicine & Molecular Imaging Annual Meeting
June 03, 2022 08:00 ET
|
Attralus, Inc
Final Phase 1/2 Study Results for AT-01 (Evuzamitide), Attralus's Novel Pan-Amyloid Imaging Agent for the Detection of Systemic Amyloidosis Repeat PET/CT Imaging of a Patient with Systemic Amyloidosis...
Positive New Data from Phase 1/2 Trial of AT-01 Presented at 2022 American College of Cardiology Annual Scientific Session
April 04, 2022 08:00 ET
|
Attralus, Inc
AT-01 is a first-in-class pan-amyloid imaging agent capable of detecting diverse types of amyloidSensitivity in those with previously diagnosed cardiac disease was 100% in ATTR and 93% in ALCardiac...
Sorrento Announces First Patient Treated in Phase IB AL Amyloidosis Trial with STI-6129, an Anti-CD38 Antibody-Drug Conjugate
March 18, 2021 09:00 ET
|
Sorrento Therapeutics, Inc.
STI-6129 is an antibody-drug conjugate (ADC) composed of a fully human monoclonal anti-CD38 antibody covalently bound by a proprietary chemical linker to a duostatin tubulin inhibitor.Amyloid Light...
Sorrento Receives FDA IND Clearance to Initiate a Phase I Clinical Trial of its CD38 Antibody-Drug Conjugate (ADC) STI-6129 for Patients with Amyloidosis
May 26, 2020 09:00 ET
|
Sorrento Therapeutics, Inc.
SAN DIEGO, May 26, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced it has received clearance from the U.S. Food and Drug Administration (FDA) for its...
Colchicine Market To Reach USD 1.13 Billion By 2026| Reports And Data
January 27, 2020 16:00 ET
|
Reports and Data
New York, Jan. 27, 2020 (GLOBE NEWSWIRE) -- According to the current analysis of Reports and Data, the global Colchicine market was valued at USD 553.8 million in 2018 and is expected to reach USD...